Mary S. Easton Center for Alzheimer's Research and Care, Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
J Alzheimers Dis. 2023;94(3):1075-1077. doi: 10.3233/JAD-230613.
Epileptic activity is known to exacerbate Alzheimer's disease (AD) pathology and worsen disease course. However, few studies have assessed whether treating epileptic activity with antiseizure drugs (ASDs) can improve patient outcomes. The current study by Hautecloque-Raysz et al. shows that patients with prodromal AD and epilepsy (epAD) fare well with ASD treatment, achieving seizure control in a large majority of cases using low dosage ASDs in monotherapy. Compared to slowly progressing AD patients without epilepsy, treated epAD patients experienced a similarly slow cognitive decline. These results suggest that ASDs that suppress seizures can improve outcomes in AD patients with epileptic activity.
癫痫活动已知可加重阿尔茨海默病（AD）的病理变化，并使疾病进程恶化。然而，很少有研究评估抗癫痫药物（ASD）治疗癫痫活动是否可以改善患者的预后。Hautecloque-Raysz 等人的这项研究表明，有前驱 AD 和癫痫（epAD）的患者在 ASD 治疗中表现良好，大多数情况下，使用低剂量的 ASD 单药治疗即可实现癫痫控制。与没有癫痫的进展缓慢的 AD 患者相比，接受治疗的 epAD 患者认知能力下降速度相似。这些结果表明，抑制癫痫发作的 ASD 可以改善有癫痫活动的 AD 患者的预后。
